Novocure Ltd
NASDAQ:NVCR

Watchlist Manager
Novocure Ltd Logo
Novocure Ltd
NASDAQ:NVCR
Watchlist
Price: 17.73 USD 3.74% Market Closed
Market Cap: 1.9B USD
Have any thoughts about
Novocure Ltd?
Write Note

Intrinsic Value

NVCR's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one NVCR stock under the Base Case scenario is 24.31 USD. Compared to the current market price of 17.73 USD, Novocure Ltd is Undervalued by 27%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NVCR Intrinsic Value
24.31 USD
Undervaluation 27%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Novocure Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for NVCR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about NVCR?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Novocure Ltd

Provide an overview of the primary business activities
of Novocure Ltd.

What unique competitive advantages
does Novocure Ltd hold over its rivals?

What risks and challenges
does Novocure Ltd face in the near future?

Has there been any significant insider trading activity
in Novocure Ltd recently?

Summarize the latest earnings call
of Novocure Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Novocure Ltd.

Provide P/S
for Novocure Ltd.

Provide P/E
for Novocure Ltd.

Provide P/OCF
for Novocure Ltd.

Provide P/FCFE
for Novocure Ltd.

Provide P/B
for Novocure Ltd.

Provide EV/S
for Novocure Ltd.

Provide EV/GP
for Novocure Ltd.

Provide EV/EBITDA
for Novocure Ltd.

Provide EV/EBIT
for Novocure Ltd.

Provide EV/OCF
for Novocure Ltd.

Provide EV/FCFF
for Novocure Ltd.

Provide EV/IC
for Novocure Ltd.

Show me price targets
for Novocure Ltd made by professional analysts.

What are the Revenue projections
for Novocure Ltd?

How accurate were the past Revenue estimates
for Novocure Ltd?

What are the Net Income projections
for Novocure Ltd?

How accurate were the past Net Income estimates
for Novocure Ltd?

What are the EPS projections
for Novocure Ltd?

How accurate were the past EPS estimates
for Novocure Ltd?

What are the EBIT projections
for Novocure Ltd?

How accurate were the past EBIT estimates
for Novocure Ltd?

Compare the revenue forecasts
for Novocure Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Novocure Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Novocure Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Novocure Ltd compared to its peers.

Compare the P/E ratios
of Novocure Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Novocure Ltd with its peers.

Analyze the financial leverage
of Novocure Ltd compared to its main competitors.

Show all profitability ratios
for Novocure Ltd.

Provide ROE
for Novocure Ltd.

Provide ROA
for Novocure Ltd.

Provide ROIC
for Novocure Ltd.

Provide ROCE
for Novocure Ltd.

Provide Gross Margin
for Novocure Ltd.

Provide Operating Margin
for Novocure Ltd.

Provide Net Margin
for Novocure Ltd.

Provide FCF Margin
for Novocure Ltd.

Show all solvency ratios
for Novocure Ltd.

Provide D/E Ratio
for Novocure Ltd.

Provide D/A Ratio
for Novocure Ltd.

Provide Interest Coverage Ratio
for Novocure Ltd.

Provide Altman Z-Score Ratio
for Novocure Ltd.

Provide Quick Ratio
for Novocure Ltd.

Provide Current Ratio
for Novocure Ltd.

Provide Cash Ratio
for Novocure Ltd.

What is the historical Revenue growth
over the last 5 years for Novocure Ltd?

What is the historical Net Income growth
over the last 5 years for Novocure Ltd?

What is the current Free Cash Flow
of Novocure Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Novocure Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Novocure Ltd

Current Assets 1.1B
Cash & Short-Term Investments 959.9m
Receivables 92.5m
Other Current Assets 42.9m
Non-Current Assets 126.7m
PP&E 114.5m
Other Non-Current Assets 12.2m
Current Liabilities 735m
Accounts Payable 91.3m
Short-Term Debt 557.3m
Other Current Liabilities 86.4m
Non-Current Liabilities 126.2m
Long-Term Debt 97.1m
Other Non-Current Liabilities 29.1m
Efficiency

Earnings Waterfall
Novocure Ltd

Revenue
577.7m USD
Cost of Revenue
-136.2m USD
Gross Profit
441.5m USD
Operating Expenses
-598.4m USD
Operating Income
-156.9m USD
Other Expenses
7.1m USD
Net Income
-149.8m USD

Free Cash Flow Analysis
Novocure Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

NVCR Profitability Score
Profitability Due Diligence

Novocure Ltd's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Revenue Growth Forecast
Positive 1-Year Revenue Growth
Positive 3-Years Revenue Growth
24/100
Profitability
Score

Novocure Ltd's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

NVCR Solvency Score
Solvency Due Diligence

Novocure Ltd's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Short-Term Solvency
Long-Term Solvency
Average D/E
31/100
Solvency
Score

Novocure Ltd's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NVCR Price Targets Summary
Novocure Ltd

Wall Street analysts forecast NVCR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NVCR is 27.25 USD with a low forecast of 18.18 USD and a high forecast of 42 USD.

Lowest
Price Target
18.18 USD
3% Upside
Average
Price Target
27.25 USD
54% Upside
Highest
Price Target
42 USD
137% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for NVCR?

Click here to dive deeper.

Dividends

Novocure Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for NVCR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

NVCR Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

NVCR News

Other Videos

Profile

Novocure Ltd Logo
Novocure Ltd

Country

Jersey

Industry

Health Care

Market Cap

1.9B USD

Dividend Yield

0%

Description

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The firm is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.

Contact

Saint Helier
No. 4 The Forum, Grenville Street
+441534756700.0
www.novocure.com

IPO

2015-10-01

Employees

1 167

Officers

Executive Chairman
Mr. William F. Doyle
CEO & Director
Mr. Asaf Danziger
Chief Financial Officer
Ms. Ashley Cordova
General Counsel
Mr. Barak Ben Arye
Executive VP & President of Novocure Oncology
Mr. Frank Leonard
Founder & CTO
Prof. Yoram Palti M.D., Ph.D.
Show More
Chief Operating Officer
Mr. Mukund Paravasthu
Chief Science Officer
Dr. Moshe Giladi Ph.D.
VP of Investor Relations
Ms. Ingrid Goldberg
Chief Human Resources Officer
Mr. Michael Puri
Show Less

See Also

Discover More
What is the Intrinsic Value of one NVCR stock?

The intrinsic value of one NVCR stock under the Base Case scenario is 24.31 USD.

Is NVCR stock undervalued or overvalued?

Compared to the current market price of 17.73 USD, Novocure Ltd is Undervalued by 27%.

Back to Top